8 relations: Carcinoid syndrome, DOTA-TATE, Krenning score, Neuroendocrine tumor, Octreotide, Radiation therapy, Therapeutic index, VIPoma.
Carcinoid syndrome
Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary to carcinoid tumors.
New!!: Peptide receptor radionuclide therapy and Carcinoid syndrome · See more »
DOTA-TATE
DOTA-TATE (Also known as DOTA-octreotate, oxodotreotide and DOTA-(Tyr3)-octreotate/ DOTA-0-Tyr3-Octreotate) is an amino acid peptide, with a covalently bonded DOTA bifunctional chelator.
New!!: Peptide receptor radionuclide therapy and DOTA-TATE · See more »
Krenning score
The Krenning score is used to grade the uptake intensity of neuroendocrine tumors on somatostatin receptor imaging such as octreotide scan.
New!!: Peptide receptor radionuclide therapy and Krenning score · See more »
Neuroendocrine tumor
Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems.
New!!: Peptide receptor radionuclide therapy and Neuroendocrine tumor · See more »
Octreotide
Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone.
New!!: Peptide receptor radionuclide therapy and Octreotide · See more »
Radiation therapy
Radiation therapy or radiotherapy, often abbreviated RT, RTx, or XRT, is therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells and normally delivered by a linear accelerator.
New!!: Peptide receptor radionuclide therapy and Radiation therapy · See more »
Therapeutic index
The therapeutic index (TI; also referred to as therapeutic ratio) is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes toxicity.
New!!: Peptide receptor radionuclide therapy and Therapeutic index · See more »
VIPoma
A VIPoma (also known as Verner–Morrison syndrome, after the physicians who first described it) is a rare (1 per 10,000,000 per year) endocrine tumor, usually (about 90%) originating from non-β islet cell of the pancreas, that produce vasoactive intestinal peptide (VIP).
New!!: Peptide receptor radionuclide therapy and VIPoma · See more »
Redirects here:
References
[1] https://en.wikipedia.org/wiki/Peptide_receptor_radionuclide_therapy